ClinicalTrials.gg
RecruitingNCT07856212Updated Oct 2, 2026

Maintenance Therapy in Metastatic Gastric Cancer: A Multicenter Retrospective Study in Colombia

An observational study in Stomach Neoplasms, Gastric Adenocarcinoma and Metastatic Gastric Cancer, sponsored by Fundación Santa Fe de Bogota. Recruiting at 4 sites in Colombia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Fundación Santa Fe de Bogota · Observational

How we know · 8 judgments

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
150
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 22 studies in Stomach Neoplasms with a site in Colombia — 7 open to participants now, 8 under way, 2 of them phase 3. Stomach Neoplasms · Colombia.

Started
2026
with 4 others
Observational
7 of 22
6 open now
Registered
21st of 22
by date
Lead sponsor
2 of 22
Fundación Santa Fe de Bogota

Among the 22 studies in Stomach Neoplasms with a site in Colombia, this one is one of 5 that started in 2026, is one of 7 observational ones, and was the 21st registered.

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

7 of the 22 studies in Stomach Neoplasms with a site in Colombia are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Colombia have not opened yet or have stopped. Only those recruiting at a site in Colombia →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Stomach Neoplasms with a site in Colombia, or all of them as a file.
02

Study summary

Metastatic gastric cancer has a poor prognosis, and the cumulative toxicity of first-line platinum and fluoropyrimidine chemotherapy limits how long treatment can be continued. Maintenance therapy, in which patients whose disease is at least stable after induction chemotherapy continue on a less toxic regimen, is increasingly used, most often with fluoropyrimidines (capecitabine, 5-fluorouracil or S-1) and, in selected molecular subgroups, with immunotherapy or targeted therapy. Evidence on the outcomes of these strategies in Latin American patients is scarce.

This multicenter retrospective study will review the medical records of adults with metastatic gastric cancer treated between 2013 and 2023 at four high-complexity cancer centers in Bogotá, Colombia, who received maintenance therapy after achieving at least stable disease with induction chemotherapy. The study will describe the demographic, clinical, pathological and molecular characteristics of these patients and estimate overall survival, progression-free survival, treatment response, toxicity and mortality. The investigators will not assign or modify any treatment.

Read the detailed description

Background: Gastric cancer is the fifth most frequent cancer and the third cause of cancer-related death worldwide, with high incidence in Asia and Latin America. In Colombia, most cases are diagnosed at advanced stages. Platinum and fluoropyrimidine combinations remain the standard first-line treatment for metastatic disease, but the optimal duration of first-line chemotherapy and the role of maintenance strategies are not clearly established. The randomized phase II AIO MATEO trial showed that S-1 maintenance after induction chemotherapy achieved overall survival comparable to continued chemotherapy with less toxicity. Immunotherapy and targeted therapies (such as trastuzumab in HER2-positive disease) are also used in the maintenance setting in selected molecular subgroups. No Colombian data exist on the outcomes of these maintenance strategies.

Design: Observational, retrospective, multicenter cohort study based on review of medical records at four high-complexity cancer centers in Bogotá, Colombia: Hospital Universitario Fundación Santa Fe de Bogotá (coordinating center, through the Instituto de Cáncer Carlos Ardila Lülle), Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo (CTIC), Clínica del Country and Los Cobos Medical Center.

Population: Adults (older than 18 years) with metastatic gastric cancer diagnosed and treated between 2013 and 2023 who achieved at least stable disease by RECIST after induction chemotherapy, with ECOG performance status of 2 or less, and who subsequently received maintenance therapy. All eligible patients will be included (census sampling); no sample size calculation is required.

Data collection: Data will be abstracted from institutional medical records into a single REDCap database hosted by Fundación Santa Fe de Bogotá. Each center will have restricted user accounts limited to its own patients. Records will be coded with an alphanumeric identifier, and the identification key will remain locally at each center and will not be uploaded. Variables include demographic and clinical characteristics, comorbidities, Helicobacter pylori status, histology (WHO and Lauren classifications, differentiation), molecular markers (microsatellite instability, PD-L1, HER2), AJCC 8th edition staging, induction and maintenance regimens and number of cycles, immunotherapy and targeted therapy, adverse drug reactions, laboratory values and tumor markers, dates of progression and relapse, vital status and cause of death.

Statistical analysis: Qualitative variables will be summarized with absolute and relative frequencies and quantitative variables with means and standard deviations or medians and interquartile ranges according to their distribution. Overall and progression-free survival will be estimated with the Kaplan-Meier method and reported as medians and survival rates. Exploratory comparisons of outcomes among maintenance types (fluoropyrimidines, immunotherapy, targeted therapy) will use bivariate tests and adjusted multivariable models, considering the molecular profile as a potential effect modifier. Analyses will be performed with IBM SPSS Statistics 25.

Ethics: The study is classified as research without risk under Colombian Resolution 8430 of 1993, and individual informed consent is not required for this retrospective record review. The protocol was approved by the Comité Corporativo de Ética en Investigación of Fundación Santa Fe de Bogotá (CCEI-18065-2025) and by the ethics committees of the participating institutions. Data will be handled in accordance with the Declaration of Helsinki and Colombian Law 1581 of 2012 on personal data protection, stored securely for five years and then destroyed.

03

Conditions studied

  • Stomach Neoplasms
  • Gastric Adenocarcinoma
  • Metastatic Gastric Cancer

Browse trials for

Keywords

  • Maintenance Therapy
  • Fluoropyrimidines
  • Capecitabine
  • Fluorouracil
  • S-1
  • Immunotherapy
  • Trastuzumab
  • Overall Survival
  • Progression-Free Survival
  • Latin America
  • Colombia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults with metastatic gastric cancer diagnosed and treated between 2013 and 2023 at four high-complexity cancer centers in Bogotá, Colombia (Hospital Universitario Fundación Santa Fe de Bogotá, Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo, Clínica del Country and Los Cobos Medical Center) who received maintenance therapy after achieving at least stable disease with induction chemotherapy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients older than 18 years diagnosed with gastric cancer at a participating institution between 2013 and 2023 who received fluoropyrimidines, immunotherapy or targeted therapy as maintenance therapy.
  • At least stable disease according to criteria after initial induction treatment, with performance status of 2 or less, followed by maintenance therapy with fluoropyrimidines.
  • Medical record showing institutional oncology follow-up.

Exclusion criteria

Exclusion Criteria:

  • that do not meet the quality and adequacy criteria required for analysis.
  • No clinical or imaging follow-up at the institution after diagnosis and treatment.
  • gastric cancer treated exclusively with palliative care without fluoropyrimidine maintenance chemotherapy.
  • Discontinuation of fluoropyrimidine maintenance therapy before the first follow-up assessment because of toxicity or medical decision, without evaluation of treatment response.
  • Death during the diagnostic process before tumor classification and staging were completed.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • Maintenance Therapy Cohort

    Drug: Fluoropyrimidine Maintenance Therapy · Drug: Immune Checkpoint Inhibitor Maintenance · Drug: Targeted Therapy Maintenance

Interventions

  • DrugFluoropyrimidineStudies of FluoropyrimidineFluoropyrimidine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Fluoropyrimidine-based maintenance therapy (capecitabine, 5-fluorouracil or S-1) administered after induction chemotherapy in routine clinical practice. The study does not assign or modify treatment; exposure data are abstracted retrospectively from medical records.

    Also known as: Capecitabine, 5-Fluorouracil, S-1

  • DrugImmune checkpoint inhibitorsStudies of Immune checkpoint inhibitorsImmune checkpoint inhibitors pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Immune checkpoint inhibitors (such as nivolumab, pembrolizumab or atezolizumab) administered as part of maintenance therapy in routine clinical practice. The study does not assign or modify treatment.

    Also known as: Nivolumab, Pembrolizumab, Atezolizumab

  • DrugTargeted Therapy Maintenance

    Targeted therapy (such as trastuzumab in HER2-positive disease) administered as part of maintenance therapy in routine clinical practice. The study does not assign or modify treatment.

    Also known as: Trastuzumab

This study also gives PembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., TrastuzumabStudies of TrastuzumabTrastuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., NivolumabStudies of NivolumabNivolumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., AtezolizumabStudies of AtezolizumabAtezolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Time frame: From start of maintenance therapy until death from any cause or last follow-up, assessed up to 10 years

Secondary outcomes

  1. Progression-Free Survival

    Time frame: From start of maintenance therapy until disease progression, death or last follow-up, assessed up to 10 years

  2. Best Response to Maintenance Therapy

    Time frame: From start of maintenance therapy until disease progression or end of maintenance, assessed up to 10 years

  3. Survival Rate at 6 Months and 1, 2, 3, 4 and 5 Years

    Time frame: 6 months and 1, 2, 3, 4 and 5 years after diagnosis

  4. Number of Patients With Adverse Drug Reactions During Maintenance Therapy

    Time frame: From start of maintenance therapy until end of maintenance, assessed up to 10 years

  5. Cancer-Specific Mortality

    Time frame: From diagnosis until death or last follow-up, assessed up to 10 years

07

Study locations

4 of 4 sites recruiting
  • Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo
    Bogotá, Bogota D.C., Colombia
    Recruiting
    • Carlos Bonilla · Principal investigator
  • Clínica del Country
    Bogotá, Bogota D.C., Colombia
    Recruiting
    • Kelman Ojeda · Principal investigator
  • Hospital Universitario Fundación Santa Fe de Bogotá
    Bogotá, Bogota D.C., Colombia
    Recruiting
    • Henry Alexander Vargas · Principal investigator
  • Los Cobos Medical Center
    Bogotá, Bogota D.C., Colombia
    Recruiting
    • Diego Lizarazo · Principal investigator
08

References and documents

Publications

  • Stocker G, Lorenzen S, Ettrich T, Herz AL, Longo F, Kiani A, Venerito M, Trojan J, Mahlberg R, Moosmann N, Chibaudel B, Kubicka S, Greil R, Daum S, Geissler M, Larcher-Senn J, Keller G, Lordick F, Haag GM. S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma-final results of the randomized AIO MATEO phase II trial. ESMO Open. 2023 Jun;8(3):101572. doi: 10.1016/j.esmoop.2023.101572. Epub 2023 Jun 2. PubMed 37270871 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared. Data are obtained from a retrospective review of medical records without individual informed consent and are protected under Colombian personal data protection law (Law 1581 of 2012) and data confidentiality agreements between the participating institutions. Aggregated results will be published in a peer-reviewed journal.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Mar 2027, 14 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 2, 2026
StartActual
Jan 1, 2026
Primary completionEst.
Mar 1, 2027
CompletionEst.
Mar 1, 2027
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07856212
Lead sponsor
Fundación Santa Fe de Bogota
Collaborators
Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo, Clínica del country
Responsible party
Henry Alexander Vargas Diaz (MD, Clinical Oncologist, Fundación Santa Fe de Bogota) — Principal investigator
First posted
Oct 2, 2026
Start date
Jan 1, 2026
Primary completion
Mar 1, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Oct 2, 2026

Study contacts

Henry Alexander Vargas, MD
Contact
henry.vargas@fsfb.org.co
+57 601 6030303
Henry Alexander Vargas, MD
principal investigator · Fundación Santa Fe de Bogotá

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion